A study published around June 16, 2026, found that a substantial share of patients who discontinue GLP-1 receptor agonist medications, including semaglutide sold as Ozempic, eventually return to the drugs after experiencing weight regain or deteriorating metabolic indicators.
Researchers tracked patients over an extended follow-up period and found that the physiological drivers of obesity and type 2 diabetes do not resolve when medication stops, prompting many individuals to seek reinstatement rather than continuing to manage symptoms through lifestyle measures alone.
Clinicians commenting on the findings said the return-to-treatment pattern reflects the chronic nature of the underlying conditions these drugs address rather than any particular failure of patient adherence or motivation. Medical societies have increasingly framed obesity as a long-term condition requiring sustained management comparable to hypertension or elevated cholesterol.
Health insurers and policymakers are watching GLP-1 utilization trends closely given the medications’ high list prices. Evidence of high return rates may strengthen arguments for uninterrupted coverage over step-therapy requirements that force periodic cessation and predictably lead to relapse before coverage is reinstated.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.sciencedaily.com/news/top/health/